Seattle-based Calistoga Pharmaceuticals said today it has hired Andrew Guggenhime as its new chief financial officer. Guggenhime has an extensive network on Wall Street, after spending a decade as the chief financial officer of public biotech companies, including Facet Biotech (NASDAQ: [[ticker:FACT]]) and PDL Biopharma (NASDAQ: [[ticker:PDLI]]). Hiring a CFO with public company experience shouldn’t come as a big surprise. Calistoga CEO Carol Gallagher said back in June, when her company raised $40 million in venture capital to support development of a promising new drug for blood cancers, that she was laying the groundwork for a potential IPO.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
